SecurAcath is the Only Subcutaneous Engineered Stabilization Device that Meets the 2016 Infusion Therapy Standards of Practice

Plymouth, MN, March 16, 2016 – Interrad Medical announces the SecurAcath device is the only Subcutaneous Engineered Stabilization Device that meets the 2016 Infusion Therapy Standards of Practice recently released by the Infusion Nurses Society (INS).

The Standards provide the most comprehensive guidance related to the infusion specialty. The Standards were first published in 1977 and have been periodically revised since. For the 2016 revision, each standard underwent an extensive review to ensure each was evidence-based and clinically sound. Each standard provides criteria for action and accountability, and the practice criteria are supported by the latest available research.

Key points within the Standards covering Vascular Access Device (VAD) Stabilization:
- Consider use of an engineered stabilization device (ESD) as inadequate stabilization and securement can cause unintentional dislodgement and complications requiring premature VAD removal
- ESDs promote consistent practice among all clinicians, reduce VAD motion that can lead to complications, reduce interruption of needed infusion therapy, and may decrease cost of care
- Avoid use of tape or sutures as they are not effective alternatives to an ESD

In the 2016 Standards, a new category called Subcutaneous Engineered Stabilization Devices (ESDs) has been added. The new Standards state; subcutaneous ESDs have been successful in stabilizing PICCs and CVADs, patient outcomes and patient and inserter satisfaction have been favorable; however, additional studies with other CVADs are needed.

Another important addition to the 2016 Standards for VAD stabilization is a caution to be aware of the risk of medical adhesive-related skin injury (MARSI) associated with the use of adhesive-based ESDs. Skin injury is a major issue with adhesive securement devices that use of the SecurAcath eliminates.

“Inclusion in the Standards supports the results we have had with the SecurAcath. We have had far fewer catheter migrations and dislodgements and have eliminated skin injury issues compared to the adhesive stabilization device we used to use,” commented Mark Rowe, RNP, MNSc, VA-BC.

“We are very pleased that the Standards have added subcutaneous ESDs. The INS Standards provide guidance on best practices for vascular access and infusions and this is a significant step in the SecurAcath becoming the new standard of care for catheter securement,” said Joseph Goldberger, President and CEO of Interrad Medical.

About the SecurAcath
The SecurAcath is the only ESD that lasts the life of the line and can dramatically decrease catheter dislodgement and migration, decrease catheter replacement costs, prevent therapy interruption, improve vessel health and preservation, reduce catheter complications and lower total cost of patient care. For more information visit www.securacath.com
About Interrad Medical, Inc.
Plymouth, Minnesota-based Interrad Medical, Inc. is a developer, manufacturer and marketer of medical devices designed for minimally-invasive interventional and surgical procedures. The Company was founded by practicing Interventional Radiologist and Interrad Medical Chairman and Chief Medical Officer, Michael Rosenberg, M.D.

This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with litigation, clinical trials, the regulatory approval process, reimbursement policies and commercialization of new technologies.